Literature DB >> 20083162

Genetics and phenomics of selenoenzymes--how to identify an impaired biosynthesis?

Lutz Schomburg1.   

Abstract

Expression of selenoenzymes relies on the Se supply and specific cis- and trans-acting factors. Two inherited defects are caused by dysfunctional selenoproteins or insufficient biosynthesis, i.e., selenoprotein N-related myopathy and impaired selenoprotein translation secondary to hypomorphic mutations in SBP2. The latter affects biosynthesis of many selenoenzymes including the deiodinase activities. A strategy to identify individuals carrying a mutation in a specific selenoprotein gene can be based on its expression pattern, enzymatic function and respective mouse model. Alternatively, reduced serum selenium and a characteristic pattern of thyroid hormone concentrations are indicative of an impaired selenoprotein biosynthesis machinery. The failure of T4 to suppress TSH or of selenite to increase serum Se will verify this suspicion. These diagnostic tests might provide a fast, cost-effective and suitable way for identifying individuals with respective selenoprotein-dependent impairments. A careful diagnosis and thoughtful monitoring will help the affected individuals to minimize their predisposition to various diseases. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20083162     DOI: 10.1016/j.mce.2010.01.011

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  3 in total

1.  [Synthesis, metabolism and diagnostics of thyroid hormones].

Authors:  J Köhrle; G Brabant
Journal:  Internist (Berl)       Date:  2010-05       Impact factor: 0.743

Review 2.  Selenium, selenoproteins and the thyroid gland: interactions in health and disease.

Authors:  Lutz Schomburg
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

3.  Polymorphisms in thioredoxin reductase and selenoprotein K genes and selenium status modulate risk of prostate cancer.

Authors:  Catherine Méplan; Sabine Rohrmann; Astrid Steinbrecher; Lutz Schomburg; Eugène Jansen; Jakob Linseisen; John Hesketh
Journal:  PLoS One       Date:  2012-11-01       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.